consent for semaglutide forms Prior Authorization Reimbursement Request Form Compound Semaglutide

Stopping semaglutide abruptly often leads to rapid rebound, with reports of a 50% increase in appetite within the first week, and about 70% of patients experience weight regain after abrupt discontinuation

Compounding pharmacies create custom formulations based on individual prescriptions, and these formulations typically lack the proprietary stabilizers found in brand-name products

The FDA recommends heart rate monitoring for all patients taking tirzepatide, particularly those with pre-existing cardiac disease, arrhythmias, heart failure, or coronary artery disease

Retrieved from Lasikiewicz, N., Myrissa, K., Hoyland, A., et al